

## Index

- A1C, S5, S6, S7, S12, S20, S24, S25, S26, S27, S56, S57, S59  
 advantages of, S22  
 age and, S23  
 alternatives to, S112  
 cardiovascular disease and, S116–S117  
 by CGM, S112, S113–S114  
 confirming diagnosis with, S22  
 correlation with BGM, S112  
 diabetes distress and, S94  
 equivalent eAG levels, S112  
 for diabetes screening and diagnosis, S21–S22  
 glycemic assessment by, S7, S112  
 hemoglobinopathies and, S22  
 in children, S30, S263–S264, S268, S269, S270–S271  
 in cystic fibrosis-related disease, S31  
 in gestational diabetes mellitus, S34–S35  
 in hyperglycemia, S64  
 in people with HIV, S30  
 in preclinical type 1 diabetes, S43  
 in staging type 1 diabetes, S24, S25  
 limitations, S7, S112  
 microvascular complications and, S115–S116  
 in prediabetes, S27–S28, S43–S44  
 in pregnancy, S22, S285–S286  
 other conditions affecting, S22  
 periodontal disease and, S69  
 point-of-care assays S21, S22, S112  
 race/ethnicity and, S22, S79  
 recommendations, S21–S22  
 serum glycated protein assays versus, S112  
 setting and modifying goals for, S113–S118  
 sleep and, S97
- AABC approach, S23  
 acarbose, S68, S154, S174  
 access to care, S14  
 access, to insulin, S308  
 ACCORD study, S60, S64, S116, S117, S118, S181, S182, S183, S192, S222, S236, S246  
 ACE inhibitors, S9, S56, S184, S185, S186, S195, S202, S205, S220, S222, S223–S224, S266, S271, S283, S289  
 acellular matrix tissues, S40  
 acute kidney injury, S151–S152, S181, S183, S186, S222  
 ADA consensus reports, S4, S9, S32, S54, S80, S88, S113, S147, S160, S164, S165, S179, S197, S202, S245  
 ADA evidence-grading system, S3  
 ADA Professional Practice Committee, S1, S2, S309  
 ADA scientific reviews, S4  
 ADA statements, S4  
 ADAG study, S112  
 Addison disease, S24, S59, S265  
 adolescents. *see* children and adolescents.  
 adrenal insufficiency, primary, S59, S265  
 adult-onset diabetes. *see* Type 2 diabetes.  
 ADVANCE trial, S64, S116, S117, S118, S181, S182, S183  
 advocacy statements, S307–S308  
 care of young children with diabetes in the childcare setting, S307  
 diabetes and driving, S308  
 diabetes and employment, S308  
 diabetes care in the school setting, S308  
 insulin access and affordability, S308  
 affordability, of insulin, S308  
 Affordable Care Act, S14, S274  
 African Americans, S15, S22, S23, S26, S27, S28, S29, S87, S221  
 age  
 aspirin use and, S193–S194  
 effect on A1C, S23  
 in diabetes diagnosis and classification, S23–S29  
 risk factor for diabetes, S29, S30  
 statin treatment and, S188  
 agricultural workers, migrant, S15–S16  
 AIM-HIGH trial, S192  
 albiglutide, S204, S205, S206  
 albuminuria, S9, S85, S87, S90, S119, S165, S180, S182, S185, S186, S193, S195, S199, S205, S207, 209–210, S219, S220, S221, S222–S227, S265, S267, S273  
 alcohol intake, S6, S55, S59, S65, S81, S86, S98, S119, S154, S184, S191, S235, S237, S283  
 algorithms  
 for diabetic retinopathy screening, S233  
 insulin dosing, S126, S133, S135, S222, S246, S288, S296  
 to predict hypoglycemia, S300  
 alirocumab, S188, S189, S190  
 alogliptin, S172, S196, S197, S206, S299  
 alpha-glucosidase inhibitors, S46, S148, S172  
 alpha-lipoic acid, S237  
 ambulatory glucose profile (AGP), S113, S114, S115, S131, S286  
 amputation, foot, S9, S64, S202, S203, S234, S237, S238, S239, S240  
 analogs. *see* insulin analogs.  
 angiotensin receptor blockers (ARBs), S9, S56, S184, S222, S266, S267, S271, S284, S289  
 anti-VEGF agents, S233–S234  
 antiplatelet agents, S192–S194, S247  
 antipsychotics, S28, S96, S148  
 antiretroviral therapies, S27, S30  
 anxiety disorders, S15, S56, S91, S92, S93, S94, S134, S154, S234, S263  
 ARRIVE trial, S193  
 artificial intelligence algorithms, for diabetic retinopathy, S232  
 ASCEND trial, S85, S193  
 Asian Americans, S26, S27, S28, S29, S45, S149, S153  
 aspart, S170, S173, S250  
 aspirin therapy, S10, S192–S194, S233, S248, S289  
 ASPREE trial, S193  
 atenolol, S237, S289  
 atherosclerotic cardiovascular disease (ASCVD), S57, S165, S166, S168, S169, S179–S218  
 atorvastatin, S188, S190  
 autoimmune diseases, S23, S26, S59, S265–S266, S289  
 autoimmune type 1 diabetes, S23, S24, S32, S268  
 autologous blood products, S240  
 automated insulin delivery (AID) systems, S7, S8, S83, S84, S97, S116, S119, S120, S126, S127, S133–S135, S158, S159, S160, S163, S245, S246, S262, S263, S288, S297  
 autonomic neuropathy, diabetic, S59, S89, S90, S181, S234, S235, S301  
 balloons, implanted gastric, S149  
 bariatric surgery. *see* metabolic surgery.  
 basal insulin, S10, S119, S129, S130, S131, S132, S135, S158, S159, S160, S162, S165, S169, S170, S171, S172, S173, S174, S250, S252, S253, S254, S262, S264, S285, S298, S300, S301, S302  
 bedtime dosing  
 of antihypertensives, S186  
 of insulin, S155, S162, S163, S248  
 behavioral therapy, S147–S148  
 behaviors, changes in, S6, S77–S110  
 cost considerations for medication-taking, S6, S13–S14  
 diabetes self-management education and support, S77–S80  
 for diabetes prevention, S44–S46  
 medical nutrition therapy, S80–S86  
 physical activity, S86–S90  
 in gestational diabetes, S287  
 psychosocial care, S91–S98  
 smoking cessation, S90–S91  
 supporting positive health behaviors, S91  
 well-being and, S13  
 bempedoic acid, S8, S187, S191  
 beta-carotene, S81, S85  
 beta-cell replacement therapy, S161, S164  
 biguanides, S172  
 bioengineered allogeneic cellular therapies, S240  
 bladder dysfunction, S235, S284  
 Blood Glucose Awareness Training, S121  
 blood glucose monitoring (BGM), S53, S127–S129, S160, S163  
 in hospitalized patients, S297  
 continuous glucose monitoring, S129–S132  
 correlation with A1C, S112  
 devices for, S126–S127  
 during pregnancy, S284, S285  
 in children and adolescents, S264, S269, S271  
 in intensive insulin regimens, S129  
 in older adults, S246, S251  
 in people on basal insulin, oral agents, or noninsulin injectables, S129  
 in schools, S127  
 inaccuracy of, S129  
 interfering substances, S129  
 meter standards, S128  
 optimizing device use, S128–S129  
 surveillance of, S128  
 blood pressure control. *see also* hypertension, S180–S186, S205, S219, S222  
 body mass index (BMI), S7, S10, S23, S25, S26, S31, S45, S46, S47, S56, S59, S87, S88, S146, S149, S223,  
 COVID-19 mortality and, S62  
 effects of metformin use in pregnancy on, S287, S288, S290  
 for metabolic surgery, S150, S153, S271  
 in obese patients, S146–S147, S148  
 in screening asymptomatic adults, S27  
 in screening asymptomatic children, S27, S268  
 postpartum, S290  
 bone fracture risk, S59–S62, S68  
 bone-strengthening activities, S86, S87, S261, S270

- breastfeeding. *see* lactation.  
bromocriptine, S148, S172
- calcium channel blockers, S186, S224  
canagliflozin, S62, S169, S172, S197, S200, S203, S205, S206, S207, S224, S225  
cancer, risk in diabetics, S62  
cannabis, S6, S90–S91,  
CANVAS study, S62, S197, S200–S201, S203, S207, S224, S226  
CANVAS-R study, S203  
capsaicin, topical, S236  
carbamazepine, S236  
carbohydrate intake, S26, S81, S84, S86, S158, S162–S163, S261–S262, S286  
cardiac autonomic neuropathy, diabetic, S235  
cardiac function testing, S272–S273  
cardiovascular disease, S2, S7, S179–S218  
antiplatelet agents, S192–S194  
cardiac testing, S195–S196  
heart failure, S8, S9, S10, S54, S57, S63, S68, S87, S116, S117, S118, S146, S164, S166, S167, S179–S180, S180, S181, S182, S183, S193, S195, S196, S197, S199, S200–S208, S221, S224–S227  
hypertension/blood pressure control, S180–S186  
lifestyle and pharmacologic interventions, S202–S205  
lipid management, S186–S187  
prevention of, S47  
risk calculator, S180  
screening, S194–S195  
statin treatment, S187–S192  
treatment, S196
- cardiovascular risk, S14, S16, S27, S33, S47, S54, S60, S63, S65, S67, S68, S85, S87, S88, S116–S117, S146, S153, S164–S165, S168, S179, S180–S184, S187, S188, S190, S191, S193, S194, S195–S197, S202, S204, S205, S206, S208, S210, S219–S220, S222, S223, S226, S235, S236, S245, S247, S248, S259, S261, S266–S267,
- care delivery systems, S5  
access to care and quality improvement, S14  
behaviors and well-being, S13  
care teams, S13  
chronic care model, S12  
medication cost considerations, S13–S14  
six core elements, S12  
system-level improvement strategies, S12–S13  
telehealth, S13
- care teams, S13, S91, S92, S93, S95, S127, S136, S273
- CARMELINA trial, S196, S206  
CAROLINA trial, S196, S202  
celiac disease, S24, S59, S61, S259, S265–S266  
CHAP trial, S184, S289  
Charcot neuropathy, S9, S88, S90, S237, S238, S239  
childcare, S10, S120, S262, S307  
children and adolescents, S7, S9, S258–S281  
A1C in, S30, S263–S264, S268, S269, S270–S271  
asymptomatic, risk-based screening in, S27  
cystic fibrosis-related diabetes in, S6, S21, S23, S31, S111, S135, S258, S268, S284  
diabetes care in childcare settings, S10, S120, S262, S307  
diabetes care in school setting, S127, S261, S262, S263, S268, S308
- insulin pumps in, S7, S263, S270  
maturity-onset diabetes of the young (MODY), S22, S32–S33  
monogenic diabetes syndromes, S32–S34  
neonatal diabetes, S22, S32, S33  
physical activity in, S45, S86, S87  
screening for type 1 risk, S26, S267  
screening for prediabetes and type 2, S27, S30, S268  
substance abuse, S273  
transition from pediatric to adult care, S273–S274  
type 1 diabetes in, S14, S23, S24, S46, S261–S268  
type 2 diabetes in, S268–S273
- CHIPS trial, S184, S289  
cholesterol lowering therapy, S9, S56, S187, S190, S191  
chronic care model, S11, S12, S52, S269  
chronic kidney disease, diabetic, S8, S9, S32, S53, S54, S56, S57, S66, S87, S117, S119, S120, S161, S164, S165, S166, S180, S195, S199, S209–S210, S219–S230, S244, S248, S249, S252  
acute kidney injury, S151–S152, S181, S183, S186, S222  
assessing albuminuria and GFR, S221  
diagnosis, S221  
epidemiology, S221  
interventions for, S223–S227  
referral to nephrologist, S227  
risk of progression, S223, S224, S226  
screening recommendations, S219  
staging, S221  
surveillance, S222–S223  
treatment recommendations, S219–S221
- chrononutrition, S83  
classification, S5, S22–S23  
clonidine, S237, S289  
clopidogrel, S193, S194  
closed-loop systems, S135  
do-it-yourself, S135  
hybrid, S7, S8, S135, S159, S162, S246, S297  
coaching, online, S78, S136  
cognitive capacity/impairment, S96–S97  
colesevelam, S148, S172  
collaborative care, S52–S54, S94, S95, S197–S198  
collagen vascular diseases, S59  
combination therapy, S8, S164, S165, S168–S169, S190–S191, S192, S193, S194, S205, S237, S252  
community health workers, S14, S16, S45, S52, S79, S91, S169  
community screening, S30  
community support, S5, S14, S16, S97, S262, S273  
comorbidities, S6, S9, S12, S23, S32, S43, S47, S52–S76  
assessment of, S59–S69  
autoimmune diseases, S59  
bone health and fractures, S59–S62  
cancer, S62  
cognitive impairment/dementia, S62  
COVID-19, S62–S64  
disability, S64  
hepatitis C, S64  
hyperglycemia, S64  
hypoglycemia, S64–S65  
low testosterone in men, S65  
nonalcoholic fatty liver disease, S65–S68  
obstructive sleep apnea, S68–S69  
pancreatitis, S69  
periodontal disease, S69  
prevention or delay of, S6, S43–S51
- sensory impairment, S77  
COMPASS trial, S194  
computerized prescriber order entry (CPOE), S298  
CONCEPTT study, S285, S286  
connected insulin pens, S126, S127, S133, S161, S263  
continuous glucose monitoring (CGM), S7, S8, S9, S10, S21, S31, S53, S55, S56, S78, S83, S84, S95, S111, S113–S117, S126–S127, S128, S159, S162–S163, S166  
ambulatory glucose profile in, S113, S114, S115, S131, S286  
assessment of glycemic status with, S113  
benefits of, S130  
devices for, S129–S130  
in hospitalized patients, S136, S297–S298, S299–S300  
in hypoglycemia prevention, S118, S121  
in older adults, S246, S253  
in pediatric type 1 diabetes, S263–S265  
in pediatric type 2 diabetes, S269–S271  
in pregnancy, S131–S132, S284, S286  
initiation of device use, S127  
interfering substances, S132  
intermittently scanned devices, S7, S78, S94, S129–S130, S131, S263, S264, S269  
real-time, S7, S94, S121, S129, S130, S263, S254, S269, S284, S286, S297  
side effects, S132  
continuous subcutaneous insulin infusion (CSII), S126, S127, S129–S130, S133, S135, S159, S160, S161  
contraception, S149, S152, S259, S260, S263, S266, S267, S271, S272, S273, S282–S283, S284, S289, S291  
coronary artery disease, S88, S184, S185, S186, S194, S197, S202, S205  
cost considerations, S13–S14, S149–S153, S159–S160, S165, S169, S170, S173  
counterfeit test strips, S128  
COVID-19, S5, S6, S26, S28, S54–S56, S62–S64, S80, S297  
COVID-19 vaccines, S56, S58, S64–S65, S285  
CREDENCE study, S62, S200–S201, S203, S207, S225, S226  
cystatin C, S221  
cystic fibrosis-related diabetes, S6, S21, S23, S31, S111, S135, S258, S268, S284  
Da Qing Diabetes Prevention Outcome Study, S44, S47, S48  
DAPA-CKD study, S200–S201, S203, S225, S226  
DAPA-HF study, S200–S201, S203, S206, S207  
dapagliflozin, S62, S63, S169, S172, S200–S201, S203, S204, S206, S207, S225, S226  
DARE-19 study, S63  
DASH diet, S45, S82, S184, S186  
DECLARE-TIMI 58 study, S200–S201, S203, S207, S226  
degludec, S159, S170, S172, S174, S250, S298  
delay, of symptomatic type 1 diabetes, S48  
delay, of type 2 diabetes, S5–S6, S43–S51  
lifestyle behavior change, S44–S46  
person-centered care goals, S47–S48  
pharmacologic interventions, S46–S47  
recommendations, S43, S44, S46, S4, S487  
of vascular disease and mortality, S47
- DELIVER study, S200–S201, S204, S207  
dementia, in diabetics, S62, S64, S65, S69, S96, S119, S192, S245–S246

- demographics, of diabetes care, S12–S14  
 dental practices, screening in, S30, S55, S57  
 depression, S7, S15, S56, S88, S91, S92, S93, S94, S95, S97, S134, S150, S154, S234, S236, S244, S245, S248, S251, S263, S273  
 detemir, S162, S170, S173, S250  
 devices. *see* technology.  
 Diabetes Control and Complications Trial (DCCT), S21, S22, S69, S116, S159, S264, S267  
 Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC), S69, S117, S120, S246  
 diabetes distress, S6, S9, S12, S15, S56, S91, S92, S93, S95–S96, S261, S262, S263, S273, S303  
 diabetes medical management plan (DMMP), for students, S127  
 Diabetes Prevention Impact Tool Kit, S45  
 Diabetes Prevention Program (DPP), S27, S28, S44, S45, S46, S48, S86, S136  
 Diabetes Prevention Program Outcomes Study (DPPOS), S28, S44, S46, S48, S47, S86, S168  
 Diabetes Prevention Recognition Program (DPRP), S46  
 diabetes self-management education and support (DSMES), S6, S13, S16, S54, S77–S80, S82, S94, S172  
 diabetes technology. *see* technology, diabetes.  
 diabetic ketoacidosis, S10, S23, S63, S64, S88, S91, S93, S96, S121, S131, S159, S168, S203, S208, S253, S261, S270, S284, S288, S298, S301–S302  
 diabetic kidney disease. *see also* chronic kidney disease.  
 dietary protein and, S75  
 diagnosis, S221  
 physical activity and, S90  
 finerenone in, S202, S206, S209–S210, S225, S226–S227  
 glucose-lowering medications for, S224–S227  
 multiple drug therapy, S186  
 prevention, S222  
 screening for complications of, S223  
 Diabetic Retinopathy Study (DRS), S234  
 diagnosis, S5, S6, S20–S37  
 confirmation of, S22  
 criteria for, S21  
 cystic fibrosis-related, S22, S31  
 diabetic kidney disease, S221  
 diagnostic tests, S20–S22  
 gestational diabetes, S34–S37  
 maturity onset diabetes of the young (MODY), S32, S33  
 monogenic diabetes syndromes, S32–S34  
 neonatal diabetes, S32  
 posttransplantation diabetes mellitus, S31–S32  
 prediabetes and type 2, S26–S31  
 type 1, S24–S26,  
 diagnostic tests, S20–S22  
 A1C use as, S21–S22  
 confirmation of, S22  
 criteria for, S21  
 fasting plasma glucose (FPG) test, S20, S21, S22, S23, S24, S26, S27, S30, S32, S34, S35, S36, S286, S290  
 oral glucose tolerance test (OGTT), S20, S21, S22, S26, S27, S31, S32, S33, S34, S35, S36, S286, S290  
 plasma glucose test, 2-h, S20, S21, S23, S24, S26, S27, S30, S33, S35  
 diet, *see* Medical nutrition therapy.
- Dietary Reference Intakes, S287  
 DIAMOND trial, S246  
 digital health technology, S136  
 dipeptidyl peptidase 4 (DPP4) inhibitors, S62, S68, S148, S166, S167, S168, S172, S196, S202, S250, S252, S298  
 disordered eating behavior, S56, S82, S84, S91, S92, S93, S95–S96, S261, S262, S263, S273, do-it-yourself systems, S135, S159  
 domperidone, S237  
 Dose Adjusted for Normal Eating (DAFNE), S121  
 DRCR Retina Network, S233  
 driving, and diabetes, S308  
 droxidopa, S237  
 dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP), S8, S68, S148, S149, S165, S167, S168, S169, S170, S171, S172, S174, S252  
 dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, S8, S62, S68, S148, S149, S165, S167, S168, S169, S170, S171, S172, S174, S252  
 dulaglutide, S165, S169, S172, S198, S204, S205, S206, S232, duloxetine, S236  
 dyslipidemia, S12, S13, S27, S28, S47, S56, S66, S87, S96, S97, S148, S179, S180, S191, S192, S193, S202, S231, S234, S236, S248, S259–S260, S266–S267, S270, S272
- e-cigarettes, S6, S90–S91  
 eating disorders, S82, S95, S263  
 eating patterns, S6, S44–S45, S53, S55, S68, S80, S81, S82, S84, S85, S93, S95, S96, S269, education, *see also* diabetes self-management education and support (DSMES).  
 on device use, S127  
 patient, S7, S13, S16, S120, S121, S239, S264  
 preconception, S262, S263, S273, S282–S283, S284  
 staff, S10, S128, S253, S297  
 electrical stimulation, gastric, S237, S240  
 ELIXA trial, S198–S199, S204  
 EMPA-REG OUTCOME trial, S200, S201, S203, S206–S207, S224  
 empagliflozin, S10, S62, S169, S172, S200–S201, S203–S204, S205, S206, S207, S224, S226, S269, S270, S271  
 EMPEROR-Preserved trial, S200–S201, S203, S207, S226  
 EMPEROR-Reduced trial, S200–S201, S203, S207, S226  
 employment, diabetes and, S308  
 enalapril, S205, S237  
 end-of-life care, S248, S254  
 enteral/parenteral feedings, S298, S300–S301  
 erectile dysfunction, S65, S235, S237  
 ertugliflozin, S62, S172, S200, S204, S205, S299  
 erythromycin, S237  
 erythropoietin therapy, A1C and, S22, S247  
 estimated average glucose (eAG), S112  
 ETDRS study, S233, S234  
 ethnicity, S2, S12, S15, S23, S25, S27, S28, S30, S34, S45, S62, S63, S64, S79, S112, S262, S268  
 evidence-grading system, S3  
 evolocumab, S188, S189, S190–S191  
 EXAMINE trial, S196, S197, S206  
 exenatide, S172, S198, S205, S206  
 exercise. *see* physical activity.  
 exocrine pancreas diseases, S6, S30, S69  
 EXSEL trial, S198–S199, S205  
 eye exam, S55, S57, S232, S267, S272, S283  
 ezetimibe, statins and, S187, S189, S190, S192
- family history, S23, S25, S26, S27, S28, S32, S34, S55, S59, S62, S95, S180, S193, S268, S271  
 farmworkers, migrant and seasonal, S15–16  
 fasting, S6, S10, S20, S21, S23, S25, S35, S36, S83, S119, S127, fasting plasma glucose (FPG) test, S20, S21, S22, S23, S24, S26, S27, S30, S32, S34, S35, S36, S171  
 fats, dietary, S6, S81, S85, S154, S266, S272, S284, S285, S287, FDA standards, for glucose meters, S128  
 fear of hypoglycemia, S56, S91, S92, S93, S94, S119, S121, S159, S244, S263  
 fenofibrate, S192, S234  
 fibrate, S260, S272  
 plus statin therapy, S192  
 fibrosis-4 index, S65, S66, S67, FIDELIO-DKD trial, S206, S209, S226, S227  
 FIGARO-DKD trial, S206, S209, S227  
 finerenone, S195, S202, S206, S209–S210, S225, S226–S227  
 fish skin graft, S240  
 FLOW trial, S266  
 fluvastatin, S188  
 food insecurity, S15  
 foot care, S9, S237–S241, S268  
 footwear, S90, S237, S239  
 FOURIER trial, S189  
 fracture risk, S6, S59, S60–S62, S68, gastrectomy, vertical sleeve, S153  
 gastric aspiration therapy, S149  
 gastric bypass, Roux-en-Y gastric, S153  
 gastric electrical stimulation, S237  
 gastrointestinal neuropathies, S235  
 gastroparesis, S8, S235, S237, S252  
 gemfibrozil, S192  
 genetic testing, S25, S32–S33, S66  
 genitourinary disturbances, S235  
 gestational diabetes mellitus (GDM), S10, S23, S27, S34–S37, S45, S46, S47, S81, S88, S95, S97, S132, S232–S233, S286–S288  
 definition, S34  
 diagnosis, S35–S36  
 insulin, S288  
 lifestyle and behavioral management, S287  
 management of, S286–S288  
 medical nutrition therapy, S287  
 metformin, S287  
 one-step strategy, S35  
 pharmacologic therapy, S287–S28  
 physical activity, S287  
 postpartum care, S290  
 screening, S35–S36  
 sulfonylureas, S287  
 two-step strategy, S37  
 glargine, S159, S162, S169, S170, S172, S173, S174, S250, S298  
 glimepiride, S169, S172, S196, S202  
 glipizide, S172, S252  
 glomerular filtration rate, S8, S9, S56, S61, S85, S119, S161, S165, S166, S167, S168, S185, S186, S195, S196, S199, S201, S219, S220, S221, S223, S225, S250, S267, S271  
 glucagon, S7, S8, S31, S118, S120–S121, S158, S169, S170, S208, S224, S225, S231, glucagon-like peptide 1 receptor agonists (GLP-1 RA), S8, S28, S62, S67, S68, S116, S148, S151, S152, S160, S164, S166, S167, S171, S172, S173, S195, S196, S199, S204, S209, S220, S245, S249, S269, S270, S299  
 glucocorticoid therapy, S301

- glucose meters, S7, S119, S127, S128–S129  
  counterfeit strips, S128  
  inaccuracy, S129  
  interfering substances, S129  
  optimizing use of, S128  
  oxygen, S129  
  standards, S128  
  temperature, S129  
glucose monitoring. *see* blood glucose monitoring.  
glucose-6-phosphate dehydrogenase deficiency, A1C and, S22, S112,  
glucose-lowering therapy, S33, S148, S165  
glulisine, S173, S250,  
glyburide, S10, S172, S252, S286, S287  
glycemic goals, S7, S8, S9, S10, **S111–S125**  
  assessment of glycemic status, **S111–S113**  
  cardiovascular disease outcome with, **S116–S117**  
  continuous glucose monitoring, **S113–S114**  
  for nonpregnant adults, **S116**  
  in diabetic kidney disease, **S223**  
  in hospitalized patients, **S296–S297**  
  in pregnancy, **S284–S285**  
  hypoglycemia, **S118–S121**  
  intercurrent illness, **S121**  
  in older adults, S246–S249  
  in pediatric type 1 diabetes, **S263–S265**  
  in pediatric type 2 diabetes, **S269**  
  setting and modifying A1C goals, S117–S118  
glycemic treatment, S7, **S158–S178**  
  for adults with type 1 diabetes, S158–S164  
    for adults with type 2 diabetes, S164–S174  
growth factors, S240  
guanfacine, S237
- health literacy, S14, S15, **S16**, S80, S119, S247, S262, S273  
health numeracy, S13, S14, S15, **S16**, S53, S79, S80, S83, S84, S162, S247, S261  
health promotion, S11–S19  
hearing impairment, S69  
heart failure, S8, S9, S10, S54, S57, S63, S68, S87, S116, S117, S118, S146, S164, S166, S167, S179–S180, S180, S181, S182, S183, S193, S195, S196, S197, S199, S200–S208, S221, S224–S227  
hemodialysis, A1C and, S22, S247  
hemoglobinopathies, A1C and, S35, S44, S55, S268  
hepatitis B, S222, S284  
hepatitis B vaccines, **S56**, S58, S284  
hepatitis C infection, **S64**, S284  
hepatitis, autoimmune, S24, S265  
high-intensity interval training, S6, **S88**  
Hispanic/Latino population, S15, S22, S27, S28, S79, S87  
homelessness, S5, S14, **S15**, S55, S119, S262, S273  
hospital care, S10, **S295–S306**  
  care delivery standards, **S295–S296**  
  continuous glucose monitoring, **S297**  
  diabetes care specialists in, S296  
  diabetic ketoacidosis, **S301–S302**  
  enteral/parenteral feedings, **S300**  
  glucocorticoid therapy, **S301**  
  glucose-lowering treatment in, **S298–S299**  
  glucose monitoring, **S297–S298**  
  glycemic goals in, **S296–S297**  
  hyperosmolar hyperglycemic state, **S301–S302**  
  hypoglycemia, **S299–S300**  
  insulin therapy, S298–S299  
medical nutrition therapy in, **S301**  
medication reconciliation, S302  
noninsulin therapies, S299  
perioperative care, S301  
preventing admissions and readmissions, **S303**  
self-management in, **S300**  
standards for special situations, **S300–S301**  
structured discharge communication, S302  
transition to ambulatory setting, S295, **S302–S303**  
HOT trial, S182, S183  
housing insecurity, S5, **S15**  
HPS2-THRIVE trial, S192  
human immunodeficiency virus (HIV), S22, S23, S26–S27, **S30**, S235, S284  
human regular insulin, S170, S173, S301, S302  
hybrid closed-loop systems. *see* automated insulin delivery systems.  
hydrogel, oral, S149  
hyperbaric oxygen therapy, S239, S240  
hyperglycemia, S10, S15, S21, S22, S23, S24, S25, S26, S28, S30, S31–S32, S34, S35, S47, S63, **S64**, S67, S68, S69, S83, S86, S88, S95, S97, S111, S113, S115, S121, S127, S128, S131–S132, S135, S146, S153, S165, S168, S170, S171, S221, S231, S232, S246, S247, S248, S251, S253, S254, S261–S262, S264, S269, S272, S282, S284, S285, S286, S290, S295, S296, S297, S298–S299, S301–S302  
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, S36, S285  
hyperosmolar hyperglycemic state, S10, S64, S121, S247, S269, S270, S298, S301–S302  
hypertension, S9, S12, S13, S27, S28, S45, S47, S57, S65, S66, S85, S87, S88, S97, S116, S146, S148, S159, S179, **S180–S186**, S193, S199, S202, S205, S221, S222, S223, S224, S225, S227, S231, S236, S244, S247, S248, S250, S254, S259, S260, S266, S270, **S271**, S272, S282, S284, S286, S288, S289  
hypertriglyceridemia, S85, S159, S168, S191  
hypoglycemia, **S64–S65**, **S118–S125**, S129, S130–S132, S134–S135, S136, S150–S154, S158–S165, S168–S169, S170, S174, S203, S208, S210, S223, S234, S235, S244, **S245–S246**, S249–S250, S251, S252, **S253–S254**, S261–S265, S269, S282, S282–S288, S291, S295, S296–S297, S298, **S299–S300**, S301–S302  
hypogonadism, S65, S237  
hypokalemia, S186, S220, S222  
icosapent ethyl, S85, S191, S225  
idiopathic type 1 diabetes, **S27**  
illness, intercurrent, glycemic targets in, **S121**, S129  
immune checkpoint inhibitors, S23, S26  
immune-mediated diabetes, **S24**  
immunizations, **S54–S59**  
impaired fasting glucose (IFG), S21, S24, S27, S28, S43, S48  
impaired glucose tolerance (IGT), S21, S24, S27, S28, S36, S43, S47, S48  
inclisiran, S9, S187, S189–S191  
incretin-based therapies, S31, S69, **S252**  
Indian Diabetes Prevention Program (IDPP-1), S46  
infections, S5, S26, S31–S32, S54–S59, S63, S64, S90, S134, S235, S239, S251, S252, S301  
influenza vaccines, **S56–S57**, S58  
inhaled insulin, S8, S133, S158, S160, S173  
injection techniques, S133, S161, **S160–S161**  
inpatient care. *see* hospital care.
- insulin analogs, S8, S134, S158, S159, S162, S169, S170, S174, S252, S264, S298, S302  
insulin delivery, S7, S8, S57, S83, **S132–S136**  
  automated systems, S7, S8, S83, S84–S85, S97, S116, S119, S120, S126, S127, S135, S158, S159, S160, S163, S245, S246, S262, S263, S288, S297  
do-it-yourself closed-loop systems, **S135**, S159  
injection techniques, S133, S161, **S160–S161**  
IV, transitioning to SC, **S298–S299**  
pens and syringes, **S132–S133**  
pumps, **S133–S136**  
insulin pump therapy, S128, S130, S131, **S133–S136**, S160, S162, S264, S270  
insulin resistance, S22, S23, S25, S27, S28, S30, S31, S47, S62, S65, S66, S67, S87, S97, S170, S172, S272, S284, S285, S286, S287, S288, S289, S298  
insulin secretagogues, S81, S88, S89, S120, S148, **S252**  
insulin therapy  
  access and affordability, S308  
  basal, S10, S119, **S129**, S130, S131, S132, S135, S158, S159, S160, S162, S165, S169, **S170**, S171, S172, S173, S174, S250, S252, S253, S254, S262, S264, S285, S298, S300, S301, S302  
  cost considerations, **S173**  
  dosing algorithms using machine learning, S126, S133, S135, S222, S246, S288, S296  
  in adults with type 1 diabetes, **S158–S164**  
  in adults with type 2 diabetes, **S164–S174**  
  combination injectable, **S174**  
  concentrated insulins, **S170**, S288, S299  
  in hospitalized patients, S298–S299  
  inhaled insulin, S8, S133, S158, S160, S173  
  in older adults, S250–S253  
  prandial, S128, S160, **S170**, S171, S174, S250, S262, S270, S298, S300  
insulin:carbohydrate ratio (ICR), S162  
integrated CGM devices, S130  
intensification  
  of obesity treatment, S8, S149  
  of diabetes therapy, S8, S160, S164, S168, S169, S174, S197, S141, S143, S149, S151, S154, S176  
intermittent fasting, S83  
intermittently scanned CGM devices, S7, S78, S94, S129–S130, **S131**, S263, S264, S269  
International Association of the Diabetes and Pregnancy Study Groups (IADPSG), S34–S37  
islet transplantation, S161, **S164**  
isradipine, S237
- juvenile-onset diabetes. *see* immune-mediated diabetes.
- KDIGO study, S9, S80, S221, S224  
ketoacidosis, diabetic, S10, S23, S63, S64, S88, S91, S93, S96, S121, S131, S159, S168, S203, S208, S253, S261, S270, S284, S288, S298, **S301–S302**  
kidney disease. *see* chronic kidney disease.  
Kumamoto study, S116
- lactation, **S290–S291**  
language barriers, S16  
latent autoimmune diabetes in adults (LADA), S23  
Latino/Hispanic population, S15, S22, S27, S28, S79, S87

- LEADER trial, S198–S199, S204, S224  
 lifestyle behavior changes, **S44–S46**  
   delivery and dissemination of, **S45–S46**  
   Diabetes Prevention Program, **S44**  
   for diabetes prevention, **S44–S46**  
   for hypertension, **S184**  
   for lipid management, S186–S187  
   for weight management, S147–S148  
   in older adults, **S249**  
   in pediatric type 1 diabetes, S259,  
     S266–S267  
   in pediatric type 2 diabetes, S259,  
     **S268–S271**  
   in pregnancy, S286  
   nutrition, **S44–S45**  
   physical activity, **S45**  
   to reduce ASCVD risk factors, S180, S184  
   type 1 diabetes progression and, **S46**  
 linagliptin, S172, S196, S202–S203, S206, S271  
 lipase inhibitors, S151  
 lipid management, S146, **S186–S187, S236**, S247,  
   S254  
 lipid profiles, S56, S186, S187, S259–S260, S266,  
   S267  
 liraglutide, S46, S68, S149, S151, S164, S169,  
   S172, S173, S174, S198, S204–S205, S206,  
   S224, S232  
 lispro, S170, S172, S173, S250  
 lixisenatide, S173, S174, S198, S204, S206  
 long-acting insulin, S159, S169, S170, S252,  
   S264, S269, S270  
 Look AHEAD trial, S63, S69, S83, **S147**, S202,  
   S249  
 loss of protective sensation, S235, S237, **S238**  
 lovastatin, S188
- machine learning, insulin dosing algorithms using, S296  
 macular edema, diabetic, S232–S234, S252  
 marijuana. *see* cannabis  
 maternal history, in screening children/adolescents, S27  
 maturity-onset diabetes of the young (MODY),  
   S23, **S32–S33**, S268  
 meal planning, S80, **S82–S83**, S84, S284  
 Medicaid expansion, S14  
 medical devices, for weight loss, **S149**  
 medical evaluation, S2, S3, S6, **S52–S76**, S146,  
   S161, S187  
   autoimmune diseases, **S59**  
   bone health, **S59**  
   cancer, **S62**  
   cognitive impairment/dementia, **S62**  
   comorbidities, **S59–S62**  
   comprehensive, S54, S55–S56  
   COVID-19, **S62–S64**  
   disability, **S64**  
   hepatitis C, **S64**  
   hyperglycemia, **S64**  
   hypoglycemia, **S64–S65**  
   immunizations, **S54–S59**  
   low testosterone in men, **S65**  
   nonalcoholic fatty liver disease, **S66–S68**  
   nonalcoholic steatohepatitis, **S66–S68**  
   obstructive sleep apnea, **S68–S69**  
   pancreatitis, **S69**  
   periodontal disease, **S69**  
   sensory impairment, **S69**  
   statins, **S69**  
 medical nutrition therapy, S6, S45, S54, S57, S77,  
   **S80–S88**, S113, S128, S154, S187, S259–S260,  
   S261, S285
- alcohol, **S86**  
 carbohydrates, **S84–S85**  
 eating patterns and meal planning, **S82–S83**  
 fats, **S85**  
 food insecurity and access, **S82**  
 goals of, **S80**  
 in children and adolescents with type 1 diabetes, **S261**  
 in hospitalized patients, **S301–S302**  
 in pregnancy, **S287**  
 micronutrient, and supplements, **S85–S86**  
 nonnutritive sweeteners, **S86**  
 protein, **S85**  
 sodium, **S85**  
 weight management, **S80–S82**  
 Mediterranean diet, S6, S45, S68, S81, S82, S85,  
   S186  
 meglitinides, S9, S115, S117, S119, S148, S165,  
   S172, S245, S249, S252  
 mental health. *see* Psychosocial care.  
 mental health referrals, S93, S95, S96  
 mental illness, serious, **S97**  
 metabolic surgery, S7, S8, S10, S58, S67, S68,  
   S80, S93, S145, S146, S148, **S149, S153–S154**,  
   S164, S168, **S271**  
 metformin, S10, S46–S47, S56, S61–S62, S63,  
   S68, S86, S116, S117, S148, S161, S165,  
   S168, S169, S170, S172, S195, S196, S198,  
   S200, S206, S210, S224, S225, S245,  
   **S250–S252**, S260, S269, S270–S271, S272,  
   S286, **S287–S288**, S290, S301  
 metoclopramide, S237  
 metoprolol, S206, S237  
 micronutrients, S80, S81, S83, **S85–S86**  
 microvascular complications, S2, S7, S12, S28, S31,  
   S33, S48, S55, **S90**, S96, S113, **S115–S116**, S117,  
   S159, S164, S189, S181, S234, **S267–S268**, S270,  
   S283  
 midodrine, S237  
 miglitol, S172  
 migrant farmworkers, S15–S16  
 mineralocorticoid receptor antagonist therapy, S8,  
   S185, S186, S220, S222, S223, S225, **S226–S227**  
 monogenic diabetes syndromes, S22, **S32–S34**  
 multiple daily injections (MDI), S55, S128, S129,  
   S130, S131, S132, S133–S134, S135, S160,  
   S162–S163, S270  
 myasthenia gravis, S24, S59, S256
- naltrexone/bupropion ER, S150  
 nateglinide, S46, S172, S252  
 National Diabetes Data Group, S36  
 National Diabetes Prevention Program, S45  
 National Health and Nutrition Examination Survey (NHANES), S12, S35, S69, S268  
 neonatal diabetes, S22, **S32**, S33, S258  
 nephrologist, referral to, S220, S221, **S227**  
 nephropathy, diabetic, S10, S28, S59, S60, S62,  
   S97, S115, S164, S186, S196, S199, S201,  
   S203, S224–S225, S231, S238, S259, S260,  
   **S267**, S270, **S271**, S284  
 neurocognitive function, **S245**  
 neuropathic pain, S64, S235, **S236–S237**, S268  
 neuropathy, diabetic, S9, S46, S54, S57, S59, S60,  
   S64, S69, S86, S88, S97, S115, S116, S119,  
   S120, S134, S169, S180, S202, **S234–S237**,  
   S239, S259, **S267–S268**, **S272**, S284, S301  
   auditory, S69  
   autonomic, S59, S88, **S90**, S181, S234, S235,  
   S301  
   cardiac autonomic, **S235**  
   gastrointestinal, **S235**
- genitourinary disturbances due to, **S235**  
 peripheral, S46, S59, S64, **S78**, S86, **S90**,  
   **S235**, S238  
 new-onset diabetes after transplantation (NODAT),  
   S31–S32  
 niacin + statin therapy, **S192**  
 nonalcoholic fatty liver disease (NAFLD), S55, S57,  
   **S65–S68**, S284  
 nonalcoholic steatohepatitis (NASH), S57, **S65–S68**,  
   S167  
 noninsulin treatments, S23, S25, S32, S68, S127,  
   **S129**, S131, S132, **S161–S164**, S168, S169,  
   S170, S172, S249, S250, S251, S269, S286,  
   S295, S298, **S299**, S300, S302, S308  
 noninsulin-dependent diabetes. *see* type 2 diabetes.  
 nonnutritive sweeteners, S6, S81, S86  
 NPH insulin, S159, S160, S163, S169, S170,  
   S171, S172, S173, S174, S250, S252, S298,  
   S300–S301  
 nucleoside reverse transcriptase inhibitors, S32  
 nursing homes, **S253–S254**  
 nutrition, S6, S11, S13, S16, S22, S30, S35,  
   *for diabetes prevention/delay*, **S44–S45**  
 nutrition therapy. *see* medical nutrition therapy.
- obesity, S7–S8, S9, S10, S26, S27, S28, S30, S34,  
   S44, S48, S55, S62, S65, S66, S67–S69,  
   S80–S81, **S145–S157**  
   assessment and monitoring, **S145–S147**  
   medical devices for weight loss, **S149**  
   metabolic surgery, **S149, S153–S154**  
   nutrition, physical activity, and  
    behavioral therapy, **S147–S148**  
   pharmacotherapy, **S148–S149**,  
    S150–S152  
 obstructive sleep apnea, S55, S56, **S68–S69**,  
   S97, S173, S186, S199, S260, **S272**  
 ODYSSEY OUTCOMES trial, S189  
 older adults, S9, S15, S57, S58, **S244–S257**  
   bone health in, S59–S62  
   end-of-life care, S254  
   hypoglycemia, S245–S246  
   lifestyle management, S249  
   neurocognitive function, **S245**  
   pharmacologic therapy, S250–S253  
   in skilled nursing facilities and nursing  
    homes, S253–S254  
   special considerations for, S253  
   treatment goals, S246–S249  
    *with type 1 diabetes*, S245, S246  
 one-step strategy, for GDM, **S35–S36**  
 opioid antagonist/antidepressant combination, S150  
 opioids, S236, S237  
 ophthalmologist, referral to, S90, S232, S233  
 oral agents. *see also specific drugs*. **S129**, S253,  
   S254, S288  
 oral glucose tolerance test (OGTT), S20, S21,  
   S22, S26, S27, S31, S32, S33, S34, S35, S36,  
   S286, S290  
 organ transplantation, posttransplantation  
   diabetes mellitus, S23, **S31–S32**  
 orlistat, S46, S150  
 orthostatic hypotension, S182, S234, S235, **S237**  
 overweight people, S9, S10, S27, S28, S30, S44,  
   S45, S48, S67, S80, S81, S86, S87, S116,  
   **S146–S147**, S148, S149, S180, S249,  
    children and adolescents, S9–S10, S26, S27,  
    **S268–S270**,  
    *during pregnancy*, S284, S288, S290  
 oxygen, glucose monitors and, S129  
 oxygen therapy, S240  
   *for advanced wound care*, S240

- hyperbaric, S239, S240  
topical, S237, S239, S240–S241
- P2Y12 receptor antagonists, S193, **S195**  
palliative care, S248, S253, S254  
pancreas transplantation, S161, S164  
pancreatectomy, S31, S69, S135  
pancreatic diabetes, S6, **S30–S31**  
pancreatitis, S6, S23, S27, S30, S31, **S69, S151–S152, S191, S205, S272**  
paramedics, S14, S16, S45, S52, S79, S91, S169  
pens, insulin, S7, S126, S127, **S132–S133**  
periodontal disease, S30, **S69**  
perioperative care, S10, **S301**  
peripheral arterial disease, **S238–S239**  
peripheral neuropathy, S46, S59, S64, **S78, S86, S90, S235, S238**  
pernicious anemia, S24, S59  
person-centered care goals, S12, **S47–S48, S12**  
pharmacologic approaches. *see also* specific medications, medication classes.  
for adults with type 1 diabetes, **S158–S164**  
for adults with type 2 diabetes, **S164–S174**  
for cardiovascular and renal disease, S7, **S202–S205, S209–S210, S227**  
for comorbidities, S57  
for hypertension, S184–S186  
for lipid management, S188–S192  
for neuropathic pain, S64, S235, **S236–S237, S268**  
for obesity, S7, **S148–S149, S150–S153**  
for pediatric type 2 diabetes, **S269–S271**  
for smoking cessation, S90  
in older adults, **S249–S253**  
in pregnancy, **S287–S288, S289**  
interfering substances for glucose meter readings, S129  
to delay or prevent type 2 diabetes, **S46–S47**  
to delay type 1 progression, **S48**  
to glycemic treatment, S8, **S158–S178**  
phentermine, S46, S149, S150, S152, S271  
phentermine/topiramate ER, S150  
phosphodiesterase type 5 inhibitors, S237  
photoocoagulation surgery, **S233–S234**  
physical activity, S6, S10, S11, S28, S55, S57, S61, S64, S111, S127, S128, S135, S202  
exercise and youth, **S87**  
for diabetes prevention, S44, **S45–S46**  
frequency and type of, **S87**  
glycemic control and, **S88**  
high-intensity interval training, **S88**  
in children with type 1 diabetes, **S261–S262**  
in children with type 2 diabetes, S269  
in DSMES, **S86–S90**  
in obesity management, **S147–S148**  
in older adults, S249  
in pregnancy, **S287**  
with diabetic kidney disease, **S90**  
with microvascular complications, **S90**  
pre-exercise evaluation, **S88**  
pioglitazone, S47, S62, S67, S68, S172  
PIONEER-6 trial, S198–S199  
pitavastatin, S188  
plasma glucose test, 2-h, S20, **S21, S23, S24, S26, S27, S30, S33, S35**  
pneumococcal pneumonia vaccine, **S57, S58**  
point-of-care assays  
A1c, S21, S22, S112  
blood glucose monitoring, S136, S297  
polycystic ovary syndrome, S27, S28, S260, S272, S273, S284, S286, S287
- population health, S5, **S11–S19**  
access to care, S14  
behaviors and well-being, S13  
care teams, S13  
chronic care model, S12–S13  
cost considerations, S13–S14  
quality improvement, S14  
recommendations, S11  
tailoring treatment for social context, S14–S16  
status and demographics, S12  
telehealth, S13
- postbariatric hypoglycemia, S154  
postpartum care, in diabetic women, **S289–S291**  
posttransplantation diabetes mellitus, S23, **S31–S32**  
pramlintide, S161, S172, S237  
prandial insulin, S128, S160, **S170, S171, S174, S250, S262, S270, S298, S300**  
pravastatin, S188  
prediabetes, S5, S10, S21  
criteria defining, S22  
diagnosis, S27–S28  
lifestyle changes for prevention of diabetes, **S44–S46**  
prevention of vascular disease and mortality, **S47**  
screening in adults, S26, S27, S28–S30  
screening in children and adolescents, S30  
preeclampsia, in women with diabetes, S34, S35, S184, S282, S284, S285–S286, 288  
aspirin and, S289  
pregabalin, S148, S236  
pregnancy, S10, **S282–S294**  
A1C and, S22, **S285–S286**  
continuous glucose monitoring in, **S286**  
drug considerations in, **S89**  
gestational diabetes mellitus (GDM), S23, **S34–S37, S287–S288**  
glucose monitoring in, **S285**  
glycemic goals in, **S284–S286**  
insulin physiology in, **S288**  
lactation, **S290**  
lifestyle and behavior management, **S287**  
medical nutrition therapy, **S287**  
metformin in, **S287**  
pharmacologic therapy, **S287–S288**  
physical activity in, **S287**  
postpartum care, **S289–S291**  
pre-existing type 1 and 2 diabetes in, **S288–S289**  
preconception care, **S283–S284**  
preconception counseling, **S282–S283**  
preeclampsia and aspirin, **S289**  
real-time CGM device use in, **S131–S132**  
retinopathy during, **S232–S233**  
sulfonylureas, **S287**  
prevention, type 2 diabetes, S6, S7, S9, S14, S27, **S28, S43–S51**  
lifestyle behavior change for, **S44–S43**  
person-centered care goals, **S47–S48**  
pharmacologic interventions, **S46–S47**  
of vascular disease and mortality, **S47**  
proliferative diabetic retinopathy, S90, S233  
proprotein convertase subtilisin/kerin type 9 (PCSK9) inhibitors, S8, S30, S187, S188, **S189, S190, S192**  
protease inhibitors, A1C and, S30  
protein intake, S9, S10, **S85, S158, S220, S223, S249, S270, S271**  
psychosocial care, S6, S9, S77, **S91–S98**  
anxiety disorders, **S94**
- assessment and treatment, **S92–S93**  
cognitive capacity/impairment, **S96–S97**  
depression, **S95**  
diabetes distress, **S93–S94**  
disordered eating behavior, **S95–S96**  
in pediatric type 1 diabetes, S261, **S262–S263**  
in pediatric type 2 diabetes, S273  
referral to mental health specialist, S93, S95, S96  
screening, S92  
serious mental illness, **S96**  
sleep health, S97  
pumps, insulin, **S133–S136**  
do-it-yourself closed-loop system, S135, S159  
in youth, S7, S134, S263, S270  
sensor augmented, S134
- quality improvement, S5, **S14, S295, S299**
- RAAS inhibitors, S163  
race, S22, S27, S63, S64, S79, S112, S148, S196, S198, S200, S221  
rapid-acting insulin analog, S134, S135, S159, S160, S163, S170, S173, S250, S254, S262, S285, S298, S299, S301, S302  
real-time CGM devices, S7, S94, S121, S129, S130, S263, S254, S269, S284, S286, S297  
REDUCE-IT trial, S85, S191  
referrals, S6, S14, S16, S66, S78  
for behavioral health professionals, S92  
for community screening, S30  
for comprehensive eye exam, S57, S267  
for food insecurity, S82  
for initial care management, S57  
for local community resources, S16  
for DSME, S54, S57, S78, S79  
for tobacco cessation, S54  
from dentist to primary care, S57  
to behavioral health provider, S92, S93  
to foot care specialist, S239  
to gastroenterologist, S65, S69  
to mental health professional, S93, S95, S96  
to nephrologist, S220, S221, **S227**  
to neurologist, S235  
to sleep specialist, S98, S260  
to registered dietitian nutritionist, S45, S57, S149, S261, S265, S283, S302  
registered dietitian nutritionist (RDN), S45, S57, S80, S82, S282, S285, S287, S288 43, S255, S257, S274  
reimbursement, S14, S45  
for CGM in adults with type 2 diabetes, S9  
for DSMES, S6, S78, **S79**  
religious fasting, **S83**  
repaglinide, S172, S252  
resistance training, S45, S68, S88, S249  
respiratory syncytial virus (RSV) vaccine, S57–S58  
retinopathy, diabetic, S66, S90, S115, S227, **S231–S234, S267, S272, S283**  
screening, S232–S233  
treatment, S233–S234  
visual rehabilitation, S234  
REWIND trial, S198–S199, S204  
risk calculator, for ASCVD, **S180**  
risk management  
cardiovascular disease, S8, **S179–S218**  
chronic kidney disease, S9, **S219–S230**  
risk, screening for  
type 1 diabetes, S26  
prediabetes and type 2, S27, S29  
rivaroxaban, S193, S194

- rosiglitazone, S148  
 Roux-en-Y gastric bypass, S153
- SAVOR-TIMI trial, S196, S206  
 saxagliptin, S172, S196, S206, S299  
 schizophrenia, S96  
 schools, diabetes care in, **S127**, S261, **S262**, S263, S268, S308  
 screening, S5, S6, S7, S9  
     after acute pancreatitis, S31  
     by age, S30,  
     community, S30  
     for cystic fibrosis -related diabetes, S31  
     for gestational diabetes mellitus, S34, S36  
     for neuropathy, S235–S236  
     for prediabetes and type 2 diabetes, S26–S30  
     for type 1 diabetes, S26  
     for type 2 diabetes, S27 **S240**  
     in children/adolescents, S30  
     in dental practices, S30, S55, S57  
     in people with HIV, S30  
     medications, S30  
     testing interval, S30  
     use of A1C for, S21–S22  
     use of FPG or 2-h PG for, S21
- seasonal farmworkers, S15–S16  
 self-monitoring of blood glucose (SMBG). *see* blood glucose monitoring (BGM)  
 semaglutide, S8, S46, S68, S148, S149, S150, S165, S168, S169, S172, S198–S199, S204, S205, S206, S224–S225, S226, S232, S252  
 sensor-augmented pumps, S134  
 sensory impairment, S69  
 setmelanotide, S149  
 sexual dysfunction, S235  
 sickle cell disease, A1C and, S22, S112, S284  
 simvastatin, S188, S189, S192  
 sitagliptin, S169, S172, S196, S206  
 skilled nursing facilities, S251, **S253–S254**  
 sleep health, S7, **S97–S98**  
 smart pens. *see* connected insulin pens  
 smoking cessation, S6, S10, S47, S55, S59, S77, **S90–S91**, **S273**  
 social capital, S5, S14, **S15**  
 social context, S14–S16  
 social determinants of health (SDOH), S12, S13, S14–S15, S16, S79, S92, S166  
 sodium channel blockers, S235, **S236**  
 sodium intake, S81, S84, **S85**, S184, S223  
 sodium–glucose cotransporter 2 (SGLT2) inhibitors, S8, S28, S62, S68, S84, S116, S148, S164, S166, S167, S172, S180, S195, S201, S209, S220, S222, S225, S246, S250, **S252**, S270, S299  
 SOLOIST-WHF trial, S208  
 sotagliflozin, S206, S207, **S208**  
 SPRINT trial, S181, S182, S183, S205  
 staging  
     of diabetic kidney disease, S57, **S221–S222**  
     of type 1 diabetes, S24  
 statin therapy, S8, S9, S47, S67–S68, S116, S180, S187, **S187–S192**,  
     combination therapy with, S190–S191  
 diabetes risk with, **S192**  
 high- and moderate intensity, S188  
 intolerance to, S190  
 primary prevention, **S187**, **S188**  
 secondary prevention, **S188–S189**  
     with bempedoic acid, S8, S187, **S191**  
     with ezetimibe, S189  
     with fibrate, S169, **S170**, **S192**  
     with niacin, S169, **S170**  
     with PCSK9 inhibitors, S189–S190  
 statins, S26, S30, **S57**, **S69**, S85, S192, S197, S198, S202  
 stem cell therapies, for wounds, S240  
 strength training, S44, S269  
 sulfonylureas, S9, S15, S32, S33, S62, S68, S113, S115, S116, S117, S119, S120, S148, S165, S168, S172, S174, S245, S249, S250, S252, **S287**  
 supplements, dietary, S61, S81, **S85–S86**, S141, S148, S154, S283, S284  
 surveillance  
     behavioral risk factor surveillance system, S79, S94  
     BGM system, S128  
     for foot problems, S237, S238–S239  
     of chronic kidney disease, **S222–S223**  
     of NAFLD patients, S66  
 SUSTAIN-6 trial, S198–S199, S204, S224  
 sweeteners, nonnutritive, S6, S81, S86  
 sympathomimetic amine anorectics, S150  
     in combination with antiepileptic, S150  
 syringes, insulin, **S132–S133**
- tapentadol, **S236**  
 technology, diabetes, S7, S8, S13, **S126–S144**  
     blood glucose monitoring, **S127–S129**  
     continuous glucose monitoring devices, **S129–S132**  
     general device principles, **S126–S127**  
     insulin delivery, **S132–S137**  
 technology-assisted prevention programs, S44, S45–S46, S79, S94  
 TECOS trial, S196, S206  
 TEDDY study, S26, S46  
 telehealth, S6, **S13**, S15, S45, S78–S80, S286  
 temperature  
     of glucose monitor, S129  
     perception of, S56, S234, S235, S237, S238  
 teplizumab, S48  
 testing interval, S30  
 testosterone  
     in diabetes prevention, S46  
     low, in men, **S65**  
 tetanus, diphtheria, pertussis (TDAP) vaccine, S58, S284  
 thiazide-like diuretics, S185, S186, S224  
 thiazolidinediones, S46, S59, S60, S148, S165, S206, S245, **S252**  
 thyroid disease  
     autoimmune, S33, S59, S266  
     in pediatric type 1 diabetes, S259, **S265**  
 time-restricted eating, S83  
 tirzepatide, S46, S62, S68, S148, S149, S152, S165, S168, S169, S172, S252  
 tobacco use/cessation, S6, S10, S47, S55, S59, S77, **S90–S91**, **S273**  
 training  
     blood glucose awareness, S121  
     health professionals/staff, S10, S13, S16, S79  
     high-intensity interval, S6, **S88**  
     on device use, S10  
     resistance, S6, S44, S45, S68, S79, S88  
     self-care, S16  
     strength, S44, S269  
 tramadol, **S236**  
 transfusion, A1C and, S22, S112, S247  
 transition  
     from hospital to ambulatory setting, S295, **S302–S303**  
     from IV to SC insulin, **S298–S299**  
     from pediatric to adult care, S258, **S273–S274**
- transplantation  
     islet, S161, **S164**  
     liver, S65, S66  
     organ, post-transplant diabetes mellitus after, S23, **S31–S32**  
     pancreas, S161, **S164**  
     renal, S161, S164, S196, S201, S207, S208, S221, S225  
 tricyclic antidepressants, S148, S235, **S236**  
 TWILIGHT trial, S194  
 two-hour plasma glucose (2-h PG) test, S20, S21, S23, S24, S26, S27, S30, S33, S35  
 two-step strategy, for GDM, **S36**  
 type 1 diabetes, S5, S6, S7, S8, S9, S10, S13, S14  
     beta-cell replacement therapy, S161, S164  
     in children/adolescents, **S233–S240**  
     classification, S22–S23  
     diagnosis, **S24–S26**  
     idiopathic, S27  
     immune-mediated, **S24**, **S26**  
     in hospitalized patients, S296, **S298**, S300  
     lifestyle and progression of, S46  
     insulin therapy, S158, **S159–S160**  
     noninsulin treatments, S161, **S164**  
     in older adults, S245, 246  
     peripheral neuropathy in, S234–S236  
     pregnancy in women with preexisting, S283, S284, S285, S286, **S288**, S290  
     retinopathy in, S232  
     screening, S26  
     staging, S24  
     subcutaneous insulin regimens, S159–S161, S163–S164  
     surgical treatment, **S164**  
     teplizumab to delay symptoms, S48
- type 2 diabetes, S5, S6, S7, S8, S9, S10, S12, S13, S15, S22–S23  
     in children/adolescents, **S268–S273**  
     classification, **S20–S22**  
     combination therapy, S8, S164, S165, S168–S169, **S190–S191**, **S192**, S193, S194, S205, S237, S252  
     diagnosis, **S26–S31**  
     insulin pump use in, S135  
     obesity and weight management, S29, S67, **S145–S157**, S165, S168  
     pharmacologic treatment in adults, S164–S174  
     pregnancy in women with preexisting, S288–S289  
     prevention or delay, S6, S7, S9, S14, S27, S28, **S43–S51**  
     retinopathy in, S233  
     risk test for, S29  
     screening in asymptomatic adults, S27, S28, S29  
     screening in children/adolescents, S28, S30  
     surgical treatment for, S164
- type 3c diabetes, S30
- UK Prospective Diabetes Study (UKPDS), S116, S117, S197, S205  
 ulcers, foot, S9, S56, S88, S90, S234, **S237–S241**  
 ultra-rapid-acting insulin analogs, S159, S160, S163  
 ultrasound wound debridement, S240
- vaccines. *see* immunizations.  
 vagus nerve stimulator, S149  
 vascular disease, S90, S116, S117, S181, S183, S192, S194, S202, S237  
     prevention of, in prediabetes, **S47**
- VERIFY trial, S168

- vertical sleeve gastrectomy, S153  
VERTIS CV trial, S200, S201, S204  
Veterans Affairs Diabetes Trial (VADT), S64, S116, S246  
vildagliptin, S168  
vitamin D supplementation, S46, S56, S60, S61, S81, S85–S86, S148  
VOYAGER-PAD trial, S194  
  
weight loss surgery. *see* metabolic surgery.  
weight loss/management, S7, S8, S31, S31, **S80–S82**, S83, S86, S87, S93, S96, S117, S136, **S145–S154**, S184, S186, S202, S236,  
in diabetes prevention, S44–S46, S47, S48  
in children/adolescents, S269, S271, S272  
in older adults, S249, S251, S252  
in pregnancy, S290  
in type 1 diabetes, S46, S61, S161  
in type 2 diabetes, S29, S67, S165, S168  
medical devices for, **S150**  
metabolic surgery for, **S149**, **S153–S154**  
pharmacotherapy for, **S148–S149**, S150–S152  
with NAFLD, S67–S68  
unexpected, S21, S23, S20, S24, S28, S62, S95, S253  
well-being, S6, **S13**, S35, S53, S65, **S77–S110**, S146, S234, S263  
whites, non-Hispanic, S22, S25, S27, S60, S63, S112, S196, S198, S200  
WISDM trial, S246  
Wound therapy, advanced, S239–S241  
  
Youth. *see* Children and adolescents.  
  
zoster vaccine, S59